Status of drug approval processes and regulation of medications for children

Area of Science:

• Pharmacology
• Pediatric Medicine
• Drug Regulation

Background:

• The term "therapeutic orphan" emerged in 1968, highlighting children's exclusion from FDA-approved drug indications.
• Despite the 1962 Kefauver-Harris amendments, pediatric populations remain largely unprotected regarding drug safety and efficacy.
• Approximately 80% of drugs approved by the FDA in the last 30 years carry disclaimers for pediatric use due to insufficient studies.

Discussion:

• Lack of pediatric-specific safety and efficacy studies is the primary reason for "therapeutic orphan" drugs.
• Existing data is often not utilized to amend drug labeling for pediatric indications.
• Regulatory and research initiatives are crucial for addressing this gap in pediatric pharmacotherapy.

Key Insights:

• Children are frequently excluded from approved drug indications, creating a significant public health issue.
• The absence of pediatric drug trials leads to widespread use of unapproved or "off-label" medications in children.
• Addressing the "therapeutic orphan" problem requires dedicated research and regulatory action.

Outlook:

• New FDA and National Institute of Child Health and Human Development initiatives show promise for increasing pediatric drug studies.
• Collaboration between pediatric investigators, regulatory bodies, and the pharmaceutical industry is essential.
• The goal is to achieve pharmacotherapeutic safety and efficacy standards for children comparable to those for adult patients.